Health Canada announced on 13 September 2013 plans, which it is hoped will help to address problems the country has been having with shortages of drugs in Canada.
Health Canada announces plans to tackle drug shortages
Home/Policies & Legislation
|
Posted 20/09/2013
0
Post your comment
Alberta’s Health Minister, Fred Horne, and Federal Minister of Health Rona Ambrose announced a national protocol for the public notification of drug shortages and a toolkit that identifies steps that can be taken to prevent and reduce the impact of drug shortages.
The protocol and toolkit were created from the Multi-Stakeholder Steering Committee on Drug Shortages (MSSC), which was launched in 2012 to advance collaborative work on drug shortages. The MSSC brings together representatives from industry and healthcare associations, group purchasing organizations, distributors, and federal, provincial and territorial governments.
The protocol and toolkit are being shared via the www.drugshortages.ca website. The protocol sets out clear expectations for how and when stakeholders across the supply chain share information about drug shortages. The toolkit identifies measures across the supply chain to prevent and reduce the impact of drug shortages.
As a result, manufacturers will be required to post all anticipated or actual drug shortages on www.drugshortages.ca where information on alternatives that can be used for patients will also be provided, as well as how long the drug shortage is expected to last.
Minister Horne expects publishing drug shortage information online to empower patients to be proactive members of their healthcare team, enabling them to ‘work with their pharmacist, their doctor or other care provider to explore their drug options’.
The publication of the protocol and toolkit were welcomed by Canadian pharmacists, who, according to Jeff Morrison of the Canadian Pharmacists Association (CPhA) ‘are on the front lines and see how drug shortages can negatively impact patients’. Mr Morrison added that ‘tools like these will help to improve coordination to resolve shortages quicker and provide pharmacists an early heads up so we can adapt care based on the availability of medicines.’
Related articles
Cancer drug shortages in the US
Some relief from drug shortages in the US
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.
Source: drugshortages.ca, Health Canada
Guidelines
Brazil's ANVISA updates guidance on pharmacokinetic studies for biosimilars
Canada eliminates phase III trial requirement for biosimilar approvals
Reports
Central America moves toward joint evaluation of biosimilar medicines
The US$52 billion question: can the US keep biosimilars competitive?
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Congress pushes biosimilar bills as interchangeability concerns linger
ANVISA updates understanding on biosimilar interchangeability
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
ANVISA and DINAVISA sign MoU to strengthen border surveillance and regulatory cooperation
Home/Policies & Legislation Posted 15/09/2026
Congress pushes biosimilar bills as interchangeability concerns linger
Home/Policies & Legislation Posted 02/09/2026
ANVISA updates understanding on biosimilar interchangeability
Home/Policies & Legislation Posted 22/07/2026
China's 12th VBP round accelerates shift to generics and biosimilars dual-track
Home/Policies & Legislation Posted 03/07/2026
The best selling biotechnology drugs of 2008: the next biosimilars targets
Post your comment